Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 2 L ESCC
  • 1 L GC/GEJC
  • 1L NSQ NSCLC
  • 1L SQ NSCLC
  • 2L NSCLC

This site is inteded for health care proffesional.

etapidi can help people with NSCLC respond to treatment and live longer

etapidi + chemotherapy was studied in a clinical trial of nearly 332 people who had Non-Squamous & 355 people who had Squamous NSCLC. Those included in the trial:

  • Had cancer that had spread
  • Could not have their cancer removed with surgery
  • Had not received treatment for this stage of their cancer

With etapidi + chemotherapy, people typically lived longer:

Nonsquamous Non-small lung cancer (NSCLC)

In a clinical trial involving 334 patients with non-squamous non-small cell lung cancer (NSCLC), the data below show the median progression-free survival, demonstrating that patients treated with Etapidi plus chemotherapy lived longer compared with chemotherapy alone.
Median Progression-Free Survival Nonsquamous NSCLC

Squamous Non-small lung cancer (NSCLC)

In a clinical trial involving 360 patients with non-squamous non-small cell lung cancer (NSCLC), the data below show the median progression-free survival, demonstrating that patients treated with Etapidi plus chemotherapy lived longer compared with chemotherapy alone.

Reduced the Risk of Death (HR for Progression/Death)

Nonsquamous Non-small lung cancer (NSCLC)​

The combination therapy reduced the risk of disease progression or death by 36%.

Squamous Non-small lung cancer (NSCLC)

The combination therapy significantly reduced the risk of disease progression or death by 48% to 52%, depending on the chemotherapy regimen used

How do I prepare for treatment?

Find more information and available resources.

Find out here